Iovance Biotherapeutics Inc
IOVA2.060USD
0.0000.00%
收盤 10/31, 16:00（美東）報價延遲15分鐘
704.35M總市值
虧損本益比TTM
關於 Iovance Biotherapeutics Inc 公司
Iovance Biotherapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司開發並提供針對實體瘤癌症患者的腫瘤浸潤淋巴細胞 (TIL) 療法。其主要候選產品 Amtagvi (lifileucel) 是一種腫瘤衍生的自體 T 細胞免疫療法，用於治療之前用 PD-1 阻斷抗體治療的不可切除或轉移性黑色素瘤成年患者，如果 BRAF V600 突變陽性，則使用 BRAF 抑制劑（含或不含 MEK 抑制劑）。該公司還銷售用於 Amtagvi 治療方案的 Proleukin (aldesleukin)，一種白細胞介素-2 或 IL-2 產品。其開發渠道包括在實體瘤癌症的其他治療環境中對 TIL 細胞療法進行多中心試驗。Amtagvi 和 Proleukin 是治療方案的一部分，該方案還包括淋巴細胞清除。該公司還在開發使用 TIL 的下一代療法，例如轉基因 TIL 細胞療法。
Iovance Biotherapeutics Inc簡介
公司代碼IOVA
公司名稱Iovance Biotherapeutics Inc
上市日期Jun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
員工數量838
證券類型Ordinary Share
年結日Jun 20
公司地址825 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94070
電話16502607120
網址https://www.iovance.com/
公司代碼IOVA
上市日期Jun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Iovance Biotherapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Dr. Friedrich Graf Finckenstein, M.D.
Dr. Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
暫無數據
地區USD
名稱
營收
佔比
United States
58.60M
97.75%
Rest of world
1.35M
2.25%
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
其他
68.67%
持股股東
持股股東
佔比
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
其他
68.67%
股東類型
持股股東
佔比
Investment Advisor
21.59%
Hedge Fund
16.62%
Investment Advisor/Hedge Fund
9.57%
Private Equity
8.01%
Venture Capital
7.77%
Research Firm
5.50%
Individual Investor
0.33%
Bank and Trust
0.25%
Pension Fund
0.20%
其他
30.16%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
649
251.80M
69.59%
-52.91M
2025Q2
654
271.34M
81.00%
-28.55M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
MHR Fund Management LLC
28.97M
8.01%
+4.55M
+18.63%
Jun 30, 2025
Quogue Capital L.L.C.
28.07M
7.76%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
25.03M
6.92%
-2.70M
-9.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.50M
5.39%
-1.03M
-5.02%
Jun 30, 2025
Long Focus Capital Management LLC
11.82M
3.27%
+2.57M
+27.78%
Jun 30, 2025
State Street Investment Management (US)
9.89M
2.73%
-1.15M
-10.42%
Jun 30, 2025
Millennium Management LLC
9.33M
2.58%
+9.17M
+5793.16%
Jun 30, 2025
Invenomic Capital Management LP
8.29M
2.29%
+2.80M
+51.09%
Jun 30, 2025
Two Sigma Investments, LP
7.01M
1.94%
+6.62M
+1666.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.19M
1.71%
+220.76K
+3.70%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
1.56%
iShares Genomics Immunology and Healthcare ETF
1.33%
WisdomTree BioRevolution Fund
0.64%
Tema Oncology ETF
0.54%
Invesco NASDAQ Future Gen 200 ETF
0.47%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
iShares Biotechnology ETF
0.06%
查看更多
Virtus LifeSci Biotech Products ETF
佔比1.56%
iShares Genomics Immunology and Healthcare ETF
佔比1.33%
WisdomTree BioRevolution Fund
佔比0.64%
Tema Oncology ETF
佔比0.54%
Invesco NASDAQ Future Gen 200 ETF
佔比0.47%
SPDR S&P Biotech ETF
佔比0.27%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.15%
Invesco Nasdaq Biotechnology ETF
佔比0.08%
ProShares Ultra Nasdaq Biotechnology
佔比0.08%
iShares Biotechnology ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
